Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T-cell Injection (Equecabtagene Autoleucel, Eque-cel) for the Treatment of Newly Diagnosed Mayo Stage IIIb AL Amyloidosis Patients

NCT07055724 is registered in ClinicalTrials.gov with Nanjing IASO Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07055724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07055724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T-cell Injection (Equecabtagene Autoleucel, Eque-cel) for the Treatment of Newly Diagnosed Mayo Stage IIIb AL Amyloidosis Patients
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
June 30, 2027
Enrollment
17 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis